NCT00995293View on ClinicalTrials.gov

Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

August 27, 2009

Primary Completion Date

January 26, 2018

Study Completion Date

January 26, 2018

Conditions
Head and Neck Neoplasms
Interventions
DRUG

DOCETAXEL

Intravenous

DRUG

CISPLATIN

Intravenous

DRUG

5-FLUOROURACIL

Intravenous

Trial Locations (1)

Unknown

Sanofi Administrative Office, Shanghai

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY